SLC5A2 and heart failure: Furthermore, heart failure is the 1 CV outcome for which glucose-lowering drugs, depending on type, have been shown to both increase risk (thiazolidinediones (40, 41), the dipeptidyl peptidase-4 inhibitor saxagliptin (42)) and decrease risk (SGLT2 inhibitors (43)).